Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Winter;11(1):75-82.
doi: 10.22088/cjim.11.1.75.

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma

Nazanin Bagherlou  1   2 , Safar Farajnia  3   4 , Saber Zahri  1 , Ali Dastranj Tabrizi  2   5 , Atefeh Nazari  4
Affiliations

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma

Nazanin Bagherlou et al. Caspian J Intern Med. 2020 Winter.

Abstract

Background: Ovarian carcinoma is one of the leading causes of cancer-related death among females. K-ras codon 12 mutations are commonly occurring mutations in different types of cancers and leads to resistance against anti-EGFR therapeutics. Hence, determination of mutations in k-ras gene is crucial for predicting response to anti-EGFR therapies. This study aimed to evaluate the prevalence of k-ras gene mutations and CA125 tumor marker in patients with ovarian carcinoma in Tabriz city.

Methods: Genomic DNA was extracted from 67 tissues pertained to women with ovarian carcinoma. Mutations in codon 12 and 13 of k-ras gene were analyzed by Nested PCR and RFLP methods. Titer of CA125 tumor marker was determined by ELISA.

Results: Among the 67 patients, 7 patients (10.4%) had mutation in k-ras codon 12 while none of them had mutation in k-ras codon 13. Based on the results, the frequency of various genotypes were 89.55%, 10.44%, and 0%, for GG, GA, and AA alleles, respectively. The p-value for stage I and Grade I tumors were 0.022 and 0.04, respectively, indicating a statistically significant correlation between codon 12 mutation and stage I and Grade I tumors. Furthermore, we found significant correlations among CA125 tumor marker titers and histological grade (p<0.000) and stage (p<0.000). The mean serum CA125 tumor marker levels in malignant carcinomas were 499.84 U/ml.

Conclusion: The results in this study indicated high prevalence of k-ras codon 12 mutations and high titer of CA125 tumor marker in patients with ovarian carcinoma in the study region.

Keywords: CA125; Codon 12; Ovarian carcinoma; RFLP; k-ras.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest in this study.

Figures

Figure 1
Figure 1
RFLP analysis for k-ras codon12 mutations
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Role of RAS signaling in ovarian cancer.
    Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S. Therachiyil L, et al. F1000Res. 2022 Nov 4;11:1253. doi: 10.12688/f1000research.126337.1. eCollection 2022. F1000Res. 2022. PMID: 36451660 Free PMC article. Review.

References

    1. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2:344–58. - PMC - PubMed
    1. Sadlecki P, Grzanka D, Grabiec M. Testing for NRAS mutations in serous borderline ovarian tumors and low-grade serous ovarian carcinomas. Dis Markers. 2018;2018:1497879. - PMC - PubMed
    1. Guo F, Gong H, Zhao H, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep. 2018;8:6076. - PMC - PubMed
    1. Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBio Med. 2019;41:711–6. - PMC - PubMed
    1. Porru M, Pompili L, Caruso C, et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37 - PMC - PubMed

LinkOut - more resources